Global Myeloproliferative Disorders Drugs Market (2018-2023): Size, Share & Trends Analysis - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--Sep 24, 2018--The “Global Myeloproliferative Disorders Drugs Market (2018-2023): Size, Share & Trends Analysis” report has been added to ResearchAndMarkets.com’s offering.The global myeloproliferative disorder drugs market size is expected to be valued at USD 9.26 billion by 2023., expanding at a CAGR of 3.4% during the forecast period. Availability of novel drugs, presence of a strong pipeline, rising incidence of myeloproliferative disorders due to changing lifestyles, growing geriatric population, and increasing public awareness are some of the primary growth stimulants for the market. Therapeutic development in second-line setting for Jakafi-intolerant patients is estimated to work in favor of the Ph-MPNs market.
There is a higher incidence of myeloproliferative disorders in North America and Western Europe as compared to East-Asian countries. Most patients are diagnosed with MPNs after 60 years of age, however, the diseases can occur in any age group. The U.S. will be the most prominent market for myeloproliferative disorders drugs owing to presence of a large target population.
Further key findings from the report suggest:The U.S. accounted for more than 45% of the market in 2017. Spiraling adoption of novel therapeutics and multiple product launches during the forecast period are anticipated to support the prominence of the market in global arena over the coming years.Strong unmet needs are likely to shape the future of the market and encourage development of breakthrough first-in-class therapies. Opportunities remain in the Ph- MPNs setting where there exists an unmet need for a safer drug than Jakafi with higher cure rates and lesser allergic effects.Primary go-to strategies of prominent players include collaborations for development and regional expansion in emerging markets. Companies ProfiledNovartisBristol-Myers SquibbPfizerTakedaInctyeTeva
Key Topics Covered
Chapter 1 Research Methodology
Chapter 2 Executive Summary
Chapter 3 Disease Primer and Epidemiology
Chapter 4 Global Myeloproliferative Disorders Drugs Market Overview
Chapter 5 Myeloproliferative Disorders Market: Pipeline Intelligence
Chapter 6 Company Profiles
Chapter 7 Market Outlook
For more information about this report visit https://www.researchandmarkets.com/research/79w49p/global?w=4
View source version on businesswire.com:https://www.businesswire.com/news/home/20180924005642/en/
Laura Wood, Senior Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics:Oncology Drugs
INDUSTRY KEYWORD: HEALTH ONCOLOGY PHARMACEUTICAL
SOURCE: Research and Markets
Copyright Business Wire 2018.
PUB: 09/24/2018 10:49 AM/DISC: 09/24/2018 10:49 AM